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an overall EQ-5D health status index score. SF-36 and EQ-5D data from the
2 OA studies and the low back pain study were also pooled for analysis;
comparisons versus placebo were prespeciﬁed.
Results: The intent-to-treat populations contained the following numbers
of patients: low back pain study, n = 965; OA study 1, n = 1023; OA
study 2, n = 987; DPN study, n = 389; pooled analysis, n = 2968. In the
low back pain study and OA study 1, mean changes in SF-36 scores from
baseline to endpoint were statistically signiﬁcant for tapentadol PR com-
pared with placebo for physical functioning, role-physical, bodily pain, and
the physical component summary scores (P≤0.029 for all comparisons).
In OA study 2, numerically greater improvements were observed with
tapentadol PR compared with placebo for the SF-36 physical functioning,
bodily pain, social functioning, role-emotional, and physical component
summary scores. In the DPN study, mean changes in SF-36 scores from
baseline to endpoint were statistically signiﬁcant for tapentadol PR com-
pared with placebo for role-physical, bodily pain, social functioning, and
physical component summary scores (all P≤0.012). In the pooled analysis
of SF-36 data from the 2 OA studies and the low back pain study, signiﬁcant
improvements were observed for tapentadol PR compared with placebo
for physical functioning (P<0.001), role-physical (P= 0.001), bodily pain
(P<0.001), vitality (P= 0.041), and physical component summary (P<0.001)
scores; no signiﬁcant improvements were observed for oxycodone CR
compared with placebo. In the low back pain study, OA study 1, and the
DPN study, signiﬁcantly greater improvements from baseline to endpoint
were observed in the EQ-5D health status index score with tapentadol PR
compared with placebo (all P≤0.020). In the pooled analysis of EQ-5D data
from the 2 OA studies and the low back pain study, a signiﬁcantly greater
improvement from baseline to endpoint in the EQ-5D health status index
score was seen with tapentadol PR compared with placebo (P<0.001) and
compared with oxycodone CR (P<0.001); a signiﬁcant improvement was
not observed for oxycodone CR compared with placebo.
Conclusions: Treatment with tapentadol PR (100-250 mg bid) was associ-
ated with signiﬁcant improvements in overall health and physical health
status compared with placebo across nociceptive and neuropathic pain
conditions.
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Purpose: Opioid withdrawal following treatment with tapentadol pro-
longed release (PR) was evaluated in this 1-year open-label extension study
(ClinicalTrials.gov Identiﬁer: NCT00487435).
Methods: Patients were eligible for enrollment if they completed 1 of
4 phase 3 studies: two 15-week studies that evaluated the eﬃcacy of
tapentadol PR and oxycodone controlled release (CR) compared with
placebo for chronic osteoarthritis pain (NCT00421928) or low back pain
(NCT00449176), a crossover study (two 2-week periods following a 3-week
titration with tapentadol immediate release) to assess dose conversion
between the immediate-release and prolonged-release tapentadol formu-
lations in patients with chronic low back pain (NCT00594516), or a 1-year
controlled long-term safety study of tapentadol PR and oxycodone CR
in patients with chronic osteoarthritis or low back pain (NCT00361504).
Patients who successfully completed one of the eﬃcacy or crossover studies
or who received oxycodone CR in the 1-year safety study were titrated to
their optimal therapeutic dose of tapentadol PR (100-250 mg bid) during
a titration period of up to 4 weeks then continued on their optimal dose
for up to 48 weeks during the maintenance period. Patients who received
tapentadol PR in the 1-year safety study continued on their optimal dose
determined in the parent study. The Clinical Opiate Withdrawal Scale
(COWS; 11-item scale scored from 0-48; <5 = no withdrawal, 5-12 = mild,
13-24 = moderate, 25-36 = moderately severe, and >36 = severe) and the
Subjective Opiate Withdrawal Scale (SOWS; 15-item scale, possible score
of 0-60; 60 = severe withdrawal) were used to assess opioid withdrawal in
patients who did not take opioids after study drug discontinuation. COWS
and SOWS scores were summarized according to the time of the last study
drug intake. For the COWS, the categories were ≥2 days to <5 days and
≥5 days, and for the SOWS, the categories were 1, 2, 3, 4, and ≥5 days.
Treatment-emergent adverse events (TEAEs) were recorded throughout the
study.
Results: Of the 384 patients who had a COWS assessment from ≥2 to <5
days after study drug discontinuation, 88.8%, 10.7%, and 0.5% experienced
no withdrawal, mild withdrawal, or moderate withdrawal, respectively. Of
the 321 patients who had a COWS assessment ≥5 days after discontin-
uation of tapentadol PR, 90.7% had no withdrawal; mild and moderate
withdrawal were observed in 8.7% and 0.6% of these patients, respectively.
Based on results of COWS assessments, no patients experienced moderately
severe or severe withdrawal. Mean (standard deviation) SOWS scores were
as follows: 1 day (n = 2), 4.5 (2.12); 2 days (n = 536), 8.8 (9.48); 3
days (n = 556), 9.3 (9.99); 4 days (n = 561), 7.8 (9.24); ≥5 days (n =
552), 5.6 (7.20); mean SOWS scores for all time periods were low (<10),
indicating minimal opioid withdrawal. The most common TEAEs (reported
by ≥10% of patients [N = 1154]) were headache (13.1%), nausea (11.8%),
and constipation (11.1%).
Conclusions: Results of COWS assessments completed by investigators
≥2 to <5 days following study drug discontinuation indicate that the
majority of patients experienced no opioid withdrawal. SOWS assessments
completed by patients each day immediately following study drug discon-
tinuation also indicate a low incidence of withdrawal and suggest that
opioid withdrawal peaks between Days 3 and 5. These results are similar
to those shown previously following tapentadol PR treatment and are
similar to those shown for placebo in previous placebo-controlled studies
of tapentadol PR for chronic pain. Together, these results indicate that
long-term treatment with tapentadol PR (100-250 mg bid) for up to 1 year
in this open-label extension trial was associated with a low incidence of
opioid withdrawal following treatment discontinuation without tapering in
patients with moderate to severe chronic painful osteoarthritis or chronic
low back pain.
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Aim: The present study was designed to evaluate the implantation of
alginate beads containing human mature allogenic chondrocytes for the
treatment of symptomatic cartilage defects in the knee.
Methods: A biodegradable, alginate-based biocompatible scaffold contain-
ing human mature allogenic chondrocytes was used for the treatment
of chondral and osteochondral lesions in the knee. Twenty-one patients
were clinically prospectively evaluated with use of the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual
Analogue Scale (VAS) for pain preoperatively and at 3, 6, 9, 12, 24 and 36
months of follow-up.
Results: A statistically signiﬁcant clinical improvement became apparent
after 6 months and patients continued to improve during the 36 months
of follow-up. Adverse reactions to the alginate/ﬁbrin matrix seeded with
the allogenic cartilage cells were not observed. Two of the procedures
failed. One of the patients had loosening of the periosteal ﬂap, which was
attributed to a failure of the surgical procedure. The other failure case was
the result of the poor quality and quantity of the repair tissue itself.
Discussion: The results of this pilot study show that the alginate-based
scaffold containing human mature allogenic chondrocytes is feasible for
the treatment of symptomatic cartilage defects in the knee. The described
technique provides clinical outcomes equal to those of other cartilage
repair techniques.
